DNL952

DRUG2 trials

Sponsors

Denali Therapeutics Inc.

Conditions

Late-Onset Pompe DiseaseLate-onset Pompe Disease

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

RecruitingNCT07354724

Denali Therapeutics Inc.Late-onset Pompe Disease

Start: 2026-05-12End: 2028-08-01Target: 32Updated: 2026-08-17

A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease

Not yet recruitingCTIS2025-524082-25-00

Denali Therapeutics Inc.Late-Onset Pompe Disease

Target: 2Updated: 2026-06-01